Immune Antibodies Linked to Stroke Recovery and Relapse Risk in Landmark Berlin Study

Every one of us carries antibodies that do something extraordinary: instead of hunting down microbes, they latch onto our own cell-surface receptors and tweak how those receptors behave. A new study from the PROSCIS-B cohort in Berlin, published in the Journal of Neurology, suggests that these so-called regulatory autoantibodies, which target G protein-coupled receptors, may quietly shape what happens to patients after an ischemic stroke, influencing both how well they recover over the following year and how likely they are to suffer another cardiovascular event within three years. The findings, drawn from 562 first-ever stroke patients, point to a surprisingly nuanced picture in which both abnormally high and abnormally low antibody levels carry distinct risks.

G protein-coupled receptors, or GPCRs, form one of the largest receptor families in the human body, with more than 800 members. They sit in the membranes of cells throughout the cardiovascular system, including endothelial cells lining blood vessels and cardiomyocytes in the heart, and they govern everything from vascular tone to heart rate. Regulatory autoantibodies directed against these receptors can act as agonists or antagonists depending on where they bind, effectively hijacking receptor signaling. In experimental models and patient cohorts, such antibodies have been linked to pro-hypertensive and pro-atherogenic states, arrhythmias, and cardiomyopathy. Researchers have even coined the term antibodiome to describe the idea that an imbalance in these antibodies, in either direction, may influence the pathobiology of vascular disease.

The research team, led by investigators at Charité – Universitätsmedizin Berlin, measured IgG autoantibodies against seven GPCRs in serum samples collected within three to seven days of a first-ever ischemic stroke: the alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors, the angiotensin II type 2 receptor, the endothelin B receptor, and the chemokine receptor CXCR3. Measurements were performed using a sandwich ELISA developed by CellTrend GmbH, in which antibodies are detected against epitopes presented by transfected Chinese hamster ovary cells overexpressing each human receptor. Because prior work suggested that both elevated and reduced antibody levels might be pathological, the researchers deliberately avoided assuming a linear dose-response relationship. Instead, they compared patients in the lowest antibody quartile against everyone else, and separately those in the highest quartile against the lower three quartiles.

The cohort itself was drawn from a prospective, hospital-based study of incident stroke patients recruited at three Charité campuses between 2010 and 2013. The analysis focused on mild to moderate ischemic strokes, defined by a National Institutes of Health Stroke Scale score below 16, to keep the population homogeneous. The 562 patients included had a mean age of 67 years, and 38 percent were women. Four outcomes were tracked: functional outcome at one year using the modified Rankin Scale, a combined endpoint of recurrent stroke, myocardial infarction, or death over three years, cognitive outcome measured annually with a telephone-based screening test, and the burden of cerebral small vessel disease on baseline brain imaging.

The first striking result concerned stroke etiology. For every antibody tested, the distribution of stroke subtypes differed between patients with low and high antibody levels. Patients in the lowest quartile more often had strokes caused by large artery atherosclerosis, the buildup of plaque in the major vessels supplying the brain, while those in the highest quartile more often had cardioembolic strokes, in which clots formed in the heart travel to the brain. The largest discrepancies appeared for antibodies against the alpha-1 adrenergic receptor. The researchers speculate that low levels of vasodilative antibodies, such as those targeting the angiotensin II type 2 receptor, might foster a pro-atherogenic, vasoconstrictive state that promotes large artery disease, whereas elevated beta-adrenergic antibodies, previously linked to atrial fibrillation and cardiac remodeling, could contribute to the arrhythmogenic substrate underlying cardioembolic strokes.

Functional outcome at one year told a different story. Patients with high levels of alpha-2 adrenergic receptor antibodies or endothelin B receptor antibodies had significantly worse modified Rankin Scale scores than patients with lower levels, with an odds ratio of 1.49 in both cases. Mediation analyses suggested these were direct effects rather than consequences of stroke subtype: high antibody levels were associated with roughly eight percentage points lower probability of full recovery and about 2.3 percentage points higher probability of severe disability or death. A post-hoc dose-response analysis supported a graded relationship for these two antibodies. Low antibody levels, by contrast, showed no association with functional outcome in any model.

Recurrent cardiovascular risk over three years followed the opposite pattern. Among 91 patients who experienced a recurrent stroke, myocardial infarction, or death during 1,390 person-years of follow-up, the risk was elevated in patients with low levels, not high levels, of certain antibodies. Those in the lowest quartile for angiotensin II type 2 receptor antibodies had an 86 percent higher hazard of the combined endpoint, while low alpha-2 and beta-1 adrenergic receptor antibodies carried 77 percent and 58 percent higher hazards, respectively. This echoes findings from a cohort of acute coronary syndrome patients, in which low beta-1 receptor antibodies predicted early recurrent myocardial infarction and cardiovascular death, suggesting the phenomenon may generalize across diseases and age groups.

Not every hypothesis panned out. Cognitive outcome over three years showed only very small or non-significant differences between antibody groups, and cerebral small vessel disease burden, assessed with the Wahlund Score, was unrelated to antibody levels, though the authors caution that missing imaging data and low overall small vessel disease burden limit those analyses. High levels of CXCR3 antibodies, which in the large population-based Gutenberg Health Study predicted cardiac mortality, were not associated with secondary events in the overall stroke cohort, although within the subgroup with large artery atherosclerosis strokes, high CXCR3 antibody levels were linked to an almost threefold increase in recurrent event risk, consistent with the shared pathophysiology of systemic atherosclerosis.

The authors are careful to frame the study as exploratory and hypothesis-generating. Multiple statistical tests were performed without a narrow set of predefined hypotheses, raising the possibility of false-positive findings, and the results require confirmation in independent cohorts. Serum samples were collected only once, days after the stroke, so the researchers cannot determine whether the antibodies predated the event or how their levels evolved over time. Only the IgG subclass was measured, and ELISA-based quantification is sensitive to handling and environmental factors, though repeated measurements of a subset of samples showed good agreement. The restriction to mild and moderate ischemic strokes also means the findings may not extend to severe or hemorrhagic events.

Even with those caveats, the study adds a compelling new dimension to stroke prognosis. If the associations hold up, a simple blood test measuring regulatory autoantibodies in the first week after stroke could eventually help clinicians stratify patients, identifying those at heightened risk of poor recovery or recurrent vascular events and tailoring secondary prevention accordingly. The bidirectional nature of the findings, with high levels predicting worse recovery and low levels predicting relapse, underscores the antibodiome concept: immune balance, not simply more or less antibody, may be what matters. As the authors conclude, these observations warrant deeper mechanistic research into how antibodies that modulate G protein-coupled receptors participate in the pathophysiology of cerebrovascular disease.

Subject of Research: Association of GPCR-directed regulatory autoantibodies with clinical outcomes after ischemic stroke

Article Title: Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B)

Article References: Miesenberger, A.-S., Arlt, F. A., Koschützke, L., Gebert, P., Heidecke, H., Schulze-Forster, K., Catar, R. A., Moll, G., Harms, C., Kufner, A., Liman, T., Prüss, H., Endres, M., & Sperber, P. S. (2026). Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B). Journal of Neurology, 273(10), Article 581. https://doi.org/10.1007/s00415-026-14103-6

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14103-6

Keywords: ischemic stroke, autoantibodies, G protein-coupled receptors, regulatory autoantibodies, functional outcome, cardiovascular risk, PROSCIS-B, stroke etiology, ELISA, neurology, immunology, atherosclerosis